Especially, blockade of the IL-7 signaling pathway with a JAK inhibitor tofacitinib inhibits the expansion of CD28- CTLs, which indicates that tofacitinib may have potential therapeutic effects for IgG4-RD. Here, CD28 is linked to immunoglobulin G4-related sclerosing disease.